Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Br J Haematol
; 160(2): 123-32, 2013 Jan.
Article
em En
| MEDLINE
| ID: mdl-23061882
ABSTRACT
Gamma delta (γδ) Τ cells are non-conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti-tumour activity against many cancers and suggest that γδ Τ cell-mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Citotóxicos
/
Imunoterapia Adotiva
/
Subpopulações de Linfócitos T
/
Receptores de Antígenos de Linfócitos T gama-delta
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Br J Haematol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
França